GPC Retrenches While Awaiting Satraplatin Data
This article was originally published in The Pink Sheet Daily
Executive Summary
German firm cuts 46 U.S. positions while “retaining core commercialization teams” in anticipation of oncologic’s eventual approval.
You may also be interested in...
GPC Biotech’s Satraplatin Fails To Meet Survival Endpoint In SPARC Trial
Next-generation oral platinum chemotherapy remains a Phase II asset worth partnering, CEO Seizinger maintains.
GPC Biotech’s Satraplatin Fails To Meet Survival Endpoint In SPARC Trial
Next-generation oral platinum chemotherapy remains a Phase II asset worth partnering, CEO Seizinger maintains.
GPC Biotech To Resubmit Orplatna With Overall Survival Data
Company announces it will withdraw the NDA for satraplatin for prostate cancer based on outcome of advisory committee meeting.